TOP > 外国特許検索 > Immunopotentiator and method of enhancing immunological activity with the same

Immunopotentiator and method of enhancing immunological activity with the same

外国特許コード F110003638
整理番号 A251-06WO
掲載日 2011年6月30日
出願国 欧州特許庁(EPO)
出願番号 04799849
公報番号 1702620
公報番号 1702620
出願日 平成16年11月19日(2004.11.19)
公報発行日 平成18年9月20日(2006.9.20)
公報発行日 平成26年1月8日(2014.1.8)
国際出願番号 JP2004017647
国際公開番号 WO2005063264
国際出願日 平成16年11月19日(2004.11.19)
国際公開日 平成17年7月14日(2005.7.14)
優先権データ
  • 2004JP017647 (2004.11.19) WO
  • 特願2003-431007 (2003.12.25) JP
発明の名称 (英語) Immunopotentiator and method of enhancing immunological activity with the same
発明の概要(英語) An immunopotentiator for enhancing an immunoactivity of mammals is characterized by comprising as an active ingredient a nucleic acid containing a special nucleic acid base, a derivative thereof or a plasmid having the nucleic acid containing the special nucleic acid base.
特許請求の範囲(英語) [claim1]
1. An immunopotentiator for mammals, which comprises as an active ingredient a nucleic acid that is an oligonucleotide containing a microbial nucleic acid-specific modified base which is an N **6-methyladenine base, a derivative thereof or a plasmid having said nucleic acid for use in enhancing an immunoactivity of mammals.
[claim2]
2. The immunopotentiator for use as claimed in claim 1, wherein the nucleic acid comprises a GATC sequence in which the A is an N **6-methyladenine base.
[claim3]
3. The immunopotentiator for use as claimed in claim 1 or claim 2, wherein the nucleic acid is a nucleic acid having a base sequence of SEQ ID NO: 4.
[claim4]
4. The immunopotentiator for use as claimed in any of claims 1 to 3, which further comprises as an active ingredient a nucleic acid containing a microbial nucleic acid-specific non-methylated CpG sequence or a plasmid having the nucleic acid containing the microbial nucleic acid-specific non-methylated CpG sequence.
[claim5]
5. The immunopotentiator for use as claimed in claim 4, wherein the nucleic acid containing the microbial nucleic acid-specific non-methylated CpG sequence is a nucleic acid having the base sequence of SEQ ID NO: 2.
[claim6]
6. The immunopotentiator for use as claimed in any one of claims 1 to 5, wherein the microbe is a virus or a bacterium.
[claim7]
7. The immunopotentiator for use as claimed in claim 6, wherein the bacterium is Escherichia coli.
[claim8]
8. An immunopotentiator as defined in any of claims 1, 2, 3, 6 or 7, together with a composition comprising as an active ingredient a nucleic acid containing a microbial nucleic acid-specific non-methylated CpG sequence or a plasmid having the nucleic acid containing the microbial nucleic acid-specific non-methylated CpG sequence for use in enhancing an immunoactivity of mammals, wherein said immunopotentiator and said composition are simultaneously administered to mammals.
[claim9]
9. Use of an immunopotentiator as defined in any one of claims 1 to 7 in the manufacture of a medicament for enhancing the immunoactivity of a mammal.
[claim10]
10. Use of an immunopotentiator as defined in any of claims 1, 2, 3, 6 or 7, together with a composition comprising as an active ingredient a nucleic acid containing a microbial nucleic acid-specific non-methylated CpG sequence or a plasmid having the nucleic acid containing the microbial nucleic acid-specific non-methylated CpG sequence in the manufacture of a medicament for enhancing the immunoactivity of a mammal, wherein said immunopotentiator and said composition are simultaneously administered to mammals.
[claim11]
11. A process for producing an inflammatory cytokine, which comprises administering the immunopotentiator as defined in any of claims 1 to 7 to cultured cells to enhance an immunoactivity of the cultured cells and produce the inflammatory cytokine.
[claim12]
12. A process for producing an inflammatory cytokine, which comprises simultaneously administering to cultured cells the immunopotentiator as defined in any of claims 1, 2, 3, 6 or 7, together with a composition comprising as an active ingredient a nucleic acid containing a microbial nucleic acid-specific non-methylated CpG sequence or a plasmid having the nucleic acid containing the microbial nucleic acid-specific non-methylated CpG sequence to further enhance an immunoactivity and produce the inflammatory cytokine.
[claim13]
13. An immunopotentiator for mammals, which comprises as an active ingredient a nucleic acid containing a microbial nucleic acid-specific modified base which is an N **6-methyladenine base wherein said nucleic acid has a base sequence of SEQ ID NO: 4, a derivative thereof or a plasmid having said nucleic acid.
[claim14]
14. The immunopotentiator of claim 13, which further comprises the features as defined in any one of claims 4 to 7.
  • 出願人(英語)
  • JAPAN SCIENCE AND TECHNOLOGY AGENCY
  • 発明者(英語)
  • KAMIYA HIROYUKI
  • HARASHIMA HIDEYOSHI
  • TSUCHIYA HIROYUKI
国際特許分類(IPC)
欧州特許分類/主・副
  • A61K031/7115
  • A61K039/39
  • C12N015/117
  • K61K039/53
  • K61K039/555B7
  • M12N310/333
指定国 Contracting States: CH DE FR GB LI
参考情報 (研究プロジェクト等) CREST Creation of Bio-Devices and Bio-Systems with Chemical and Biological Molecules for Medical Use AREA
ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close